Intelligent Spine Interface for Spinal Cord Injury

(ISI-C Trial)

KB
JS
OL
Overseen ByOwen Leary, BS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new device called the Intelligent Spine Interface, designed to help people with spinal cord injuries regain movement in their lower limbs. Researchers aim to understand how nerve signals travel within the injured spinal cord using this device. The trial involves imaging, surgery to implant part of the device, and physical rehabilitation. It suits individuals who had a spinal cord injury over a year ago, have completed rehabilitation, and can use their upper body to move with a wheelchair or crutches. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could transform spinal cord injury treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you have an intrathecal baclofen or morphine pump, you cannot participate in the trial.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you have a medication-related bleeding disorder or use certain implanted devices, you may not be eligible to participate.

What prior data suggests that this device is safe for spinal cord injury patients?

Research shows limited safety information for the Intelligent Spine Interface (ISI) in spinal cord injury treatments. Only about 30% of trials have shared detailed safety data. This lack of comprehensive safety data from past studies means the device's safety remains partially understood during testing.

For new medical devices like this one, safety information is crucial. Studies on similar spinal cord devices suggest potential benefits but also highlight the need for close monitoring of risks and side effects.

Without full safety data, it's important to recognize this as an early-stage trial. This typically means the device is still under evaluation for safety and effectiveness. Participants should consider this when deciding to join the trial.12345

Why are researchers excited about this trial?

Most treatments for spinal cord injuries focus on physical rehabilitation or medications to manage symptoms, but the Intelligent Spine Interface is different. This innovative approach works by creating a direct communication link between the brain and the spinal cord using advanced neural interfaces. Researchers are excited because it has the potential to restore voluntary movement and sensation by bypassing damaged areas of the spinal cord, offering new hope for patients with complete or incomplete spinal cord injuries. Unlike current options, which often provide limited recovery, this method could dramatically improve quality of life by enabling more natural control over movement.

What evidence suggests that the Intelligent Spine Interface is effective for spinal cord injury?

Research shows that devices like the Intelligent Spine Interface, studied in this trial, can help people with spinal cord injuries regain movement. One study demonstrated that a digital connection between the brain and spinal cord enabled a person with paralysis to stand and walk naturally in everyday settings. These devices convert brain signals into electrical impulses that trigger movement. Early results suggest this technology could significantly enhance mobility and function for those with spinal cord injuries. Although the full potential is still under investigation, initial findings are promising for restoring movement.12346

Who Is on the Research Team?

DB

David Borton, PhD

Principal Investigator

Brown University

Are You a Good Fit for This Trial?

This trial is for adults aged 18-65 with spinal cord injury (SCI) between C7/T1 and T10, who are at least one year post-injury. Participants must have completed SCI rehab, be able to use their upper limbs for mobility, and commit to intensive therapy. Exclusions include pregnancy, BMI >30, co-existing neuropathies or disorders, contraindications to MRI or surgery, severe joint contractures or deformities in lower extremities.

Inclusion Criteria

The injury site is at least 4 cm away from the end of the spinal cord.
Must provide informed consent prior to study participation
My spinal cord injury is between my neck and waist and is classified as severe or moderate.
See 5 more

Exclusion Criteria

I have a birth defect or injury affecting my legs.
I have nerve damage in my legs or lower back issues.
I have a blood disorder or take medication that makes surgery unsafe.
See 13 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Pre-rehabilitation

Baseline review of SCI related standardized outcome measures to understand if the device/treatment is producing the desired effect on the participant's physical function

2-4 weeks

Surgery

Pre-surgery testing, anesthesia administration, lead placement above and below the site of injury, wound closure and observation

1 week

Inpatient Rehabilitation

Daily physical rehabilitation sessions in specialized gaits lab, neurostimulation protocol, follow-up SCI-related outcome measures review

4-6 months

Surgery

Surgically implanted leads will be removed

1 week

Follow-up

Follow-up physical and neurological exams to assess if there is a change in function since baseline

4-8 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Intelligent Spine Interface
Trial Overview The study tests a new device called Intelligent Spine Interface (ISI-C), designed to help SCI patients regain lower limb function by understanding nervous system signals within the spinal cord. It involves imaging studies like X-rays, surgical implantation of ISI-C, body function assessments (balance/movement/gait), and physical rehabilitation.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: SCI PatientExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rhode Island Hospital

Lead Sponsor

Trials
275
Recruited
71,400+

US Department of Veterans Affairs

Collaborator

Trials
881
Recruited
502,000+

Brown University

Collaborator

Trials
480
Recruited
724,000+

Intel Corporation

Industry Sponsor

Trials
10
Recruited
28,800+

Nuvectra

Industry Sponsor

Trials
3
Recruited
110+

Boston Scientific Corporation

Industry Sponsor

Trials
758
Recruited
867,000+
Michael F. Mahoney profile image

Michael F. Mahoney

Boston Scientific Corporation

Chief Executive Officer since 2016

MBA from Wake Forest University, BBA in Finance from the University of Iowa

Kenneth Stein profile image

Kenneth Stein

Boston Scientific Corporation

Chief Medical Officer since 2020

MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology

Published Research Related to This Trial

The development of a miniaturized brain-machine-spinal cord interface (BMSI) shows promise for restoring mobility in individuals with spinal cord injuries by converting neural signals into electrical stimuli for the spinal cord.
In a proof-of-concept study with anesthetized rats, the BMSI successfully activated distinct muscle patterns through intraspinal microstimulation, demonstrating the potential for real-time control of movement based on brain activity.
Cortical control of intraspinal microstimulation: Toward a new approach for restoration of function after spinal cord injury.Shahdoost, S., Frost, S., Dunham, C., et al.[2020]
In a study of 444 adults with traumatic spinal cord injury, 79.3% experienced adverse events, with urinary tract infections and pneumonia being the most common, highlighting the high risk of complications in this patient group.
Older age and more severe injuries were linked to increased adverse events, while certain modifiable comorbidities, like substance use and psychiatric conditions, were associated with specific risks such as delirium and pneumonia, suggesting that addressing these factors could help reduce complications.
Previously Identified Common Post-Injury Adverse Events in Traumatic Spinal Cord Injury-Validation of Existing Literature and Relation to Selected Potentially Modifiable Comorbidities: A Prospective Canadian Cohort Study.Marion, TE., Rivers, CS., Kurban, D., et al.[2019]
In a study of 171 patients with traumatic spinal cord injury (TSCI), over 77% experienced adverse events (AEs) during acute hospital care, with urinary tract infections and pneumonias being the most common, highlighting the need for improved monitoring and prevention strategies.
The presence of certain AEs, such as decubitus ulcers and delirium, significantly increased the length of hospital stay, indicating that these complications can lead to longer recovery times, although acute AEs did not impact health-related quality of life at the time of discharge.
Incidence of acute care adverse events and long-term health-related quality of life in patients with TSCI.Street, JT., Noonan, VK., Cheung, A., et al.[2015]

Citations

Study Details | Intelligent Spine Interface, Clinical (ISI-C)This research study is being done to test a new device developed for spinal cord injury (SCI) patients. The purpose of this study is to collect data on how ...
Walking naturally after spinal cord injury using a brain– ...A digital bridge between the brain and spinal cord that enabled an individual with chronic tetraplegia to stand and walk naturally in community settings.
Intelligent Spine Interface for Spinal Cord Injury (ISI-C Trial)Research shows that miniaturized neural interfaces can help restore function and mobility in spinal cord injuries by converting brain signals into electrical ...
A direct spinal cord–computer interface enables the control of ...This non-invasive neural interface allows the investigation of motor neuron changes after the injury and has the potential to promote movement restoration.
Navigating the complexities of spinal cord injuryThis review covers the pathophysiology of SCI, pharmacological and non-pharmacological strategies currently being researched, as well as various interventions ...
Intelligent Spine InterfaceThe Intelligent Spine Interface (ISI) research program aims to bridge the gap in spinal cord injury through integration of advanced AI/ML strategies, ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security